Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Debt to Equity (2018 - 2023)

Protagonist Therapeutics (PTGX) has disclosed Debt to Equity for 6 consecutive years, with $0.0 as the latest value for Q2 2023.

  • Quarterly Debt to Equity fell 88.61% to $0.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $0.0 through Jun 2023, down 88.61% year-over-year, with the annual reading at $0.0 for FY2022, 89.32% down from the prior year.
  • Debt to Equity hit $0.0 in Q2 2023 for Protagonist Therapeutics, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.03 in Q2 2021 to a low of $0.0 in Q2 2023.
  • Historically, Debt to Equity has averaged $0.01 across 5 years, with a median of $0.01 in 2019.
  • Biggest five-year swings in Debt to Equity: soared 432.37% in 2021 and later tumbled 99.06% in 2022.
  • Year by year, Debt to Equity stood at $0.02 in 2019, then tumbled by 38.09% to $0.01 in 2020, then plummeted by 69.33% to $0.0 in 2021, then plummeted by 89.32% to $0.0 in 2022, then tumbled by 89.37% to $0.0 in 2023.
  • Business Quant data shows Debt to Equity for PTGX at $0.0 in Q2 2023, $0.0 in Q1 2023, and $0.0 in Q4 2022.